查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1420934

頭頸癌市場 - 全球產業分析、規模、佔有率、成長、趨勢和預測，2023-2031 年

Head and Neck Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 178 Pages | 商品交期: 2-10個工作天內

價格

頭頸癌市場 - 報告範圍

TMR 關於全球頭頸癌市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球頭頸癌的收入2017-2031 年頸部癌症市場，以2023 年為基準年，2031 年為預測年。報告中也提供了2023年至2031年全球頭頸癌市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解頭頸癌市場。

市場概況
2023年市場價值 16 億美元
2031 年市場價值 29億美元
CAGR 6.8%

該報告深入研究了全球頭頸癌市場的競爭格局。全球頭頸癌市場的主要參與者已經確定，並且每一位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球頭頸癌市場參與者的屬性。

目錄

第 1 章：執行摘要

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 市場區隔
  • 概述
  • 市場動態
  • 2017-2031 年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：依藥物類別

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依藥品類別，2017-2031
    • EGFR抑制劑
    • 有絲分裂抑制劑
    • 抗PD-1單株抗體
    • 其他
  • 市場吸引力：按藥品類別

第 7 章：全球市場分析與預測：按配銷通路

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按配銷通路，2017-2031
    • 醫院藥房
    • 零售藥局
    • 電子商務
  • 市場吸引力：按配銷通路

第 8 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按地區

第 9 章：北美市場分析與預測

第 10 章：歐洲市場分析與預測

第 11 章：亞太市場分析與預測

第 12 章：拉丁美洲市場分析與預測

第 13 章：中東和非洲市場分析與預測

第 14 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • Sanofi
    • Pfizer
    • Eli Lilly and Company
    • F. Hoffman-La Roche
    • AstraZeneca
    • Merck KgaA
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Galera
    • Fresenius Kabi
    • Teva Pharmaceuticals
Product Code: TMRGL22919

Head and Neck Cancer Market - Scope of Report

TMR's report on the global head and neck cancer market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global head and neck cancer market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global head and neck cancer market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the head and neck cancer market.

Market Snapshot
Market Value in 2023US$ 1.6 Bn
Market Value in 2031US$ 2.9 Bn
CAGR6.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global head and neck cancer market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global head and neck cancer market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global head and neck cancer market.

The report delves into the competitive landscape of the global head and neck cancer market. Key players operating in the global head and neck cancer market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global head and neck cancer market profiled in this report.

Key Questions Answered in Global head and neck cancer Market Report:

  • What is the sales/revenue generated by head and neck cancer across all regions during the forecast period?
  • What are the opportunities in the global head and neck cancer market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Head and Neck Cancer Market - Research Objectives and Research Approach

The comprehensive report on the global head and neck cancer market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global head and neck cancer market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global head and neck cancer market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Head and Neck Cancer Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Head and Neck Cancer Market Analysis and Forecasts, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Head and Neck Cancer Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. EGFR Inhibitors
    • 6.3.2. Mitotic Inhibitors
    • 6.3.3. Anti-PD-1 Monoclonal Antibodies
    • 6.3.4. Others
  • 6.4. Market Attractiveness, by Drug Class

7. Global Head and Neck Cancer Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 7.3.1. Hospitals Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. E-commerce
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Head and Neck Cancer Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2017-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Head and Neck Cancer Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Drug Class, 2017-2031
    • 9.2.1. EGFR Inhibitors
    • 9.2.2. Mitotic Inhibitors
    • 9.2.3. Anti-PD-1 Monoclonal Antibodies
    • 9.2.4. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospitals Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. E-commerce
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Drug Class
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Head and Neck Cancer Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. EGFR Inhibitors
    • 10.2.2. Mitotic Inhibitors
    • 10.2.3. Anti-PD-1 Monoclonal Antibodies
    • 10.2.4. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.3.1. Hospitals Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. E-commerce
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Drug Class
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Head and Neck Cancer Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. EGFR Inhibitors
    • 11.2.2. Mitotic Inhibitors
    • 11.2.3. Anti-PD-1 Monoclonal Antibodies
    • 11.2.4. Others
  • 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.3.1. Hospitals Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. E-commerce
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Drug Class
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Head and Neck Cancer Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. EGFR Inhibitors
    • 12.2.2. Mitotic Inhibitors
    • 12.2.3. Anti-PD-1 Monoclonal Antibodies
    • 12.2.4. Others
  • 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.3.1. Hospitals Pharmacies
    • 12.3.2. Retail Pharmacies
    • 12.3.3. E-commerce
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Drug Class
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Head and Neck Cancer Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. EGFR Inhibitors
    • 13.2.2. Mitotic Inhibitors
    • 13.2.3. Anti-PD-1 Monoclonal Antibodies
    • 13.2.4. Others
  • 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.3.1. Hospitals Pharmacies
    • 13.3.2. Retail Pharmacies
    • 13.3.3. E-commerce
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Drug Class
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Sanofi
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Pfizer
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Eli Lilly and Company
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. F. Hoffman-La Roche
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. AstraZeneca
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Merck KgaA
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Bayer AG
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Bristol-Myers Squibb Company
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Galera
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Fresenius Kabi
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. Financial Overview
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview
    • 14.3.11. Teva Pharmaceuticals
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. Financial Overview
      • 14.3.11.4. SWOT Analysis
      • 14.3.11.5. Strategic Overview

List of Tables

  • Table 1: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 2: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 3: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 4: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 5: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 6: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 7: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 8: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 9: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 10: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 11: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 12: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 16: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 18: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031

List of Figures

  • Figure 1: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 2: Global Head and Neck Cancer Market Value Share, by Drug Class, 2022
  • Figure 3: Global Head and Neck Cancer Market Value Share, by Distribution Channel, 2022
  • Figure 4: Global Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 5: Global Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 6: Global Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 7: Global Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 8: Global Head and Neck Cancer Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 9: Global Head and Neck Cancer Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 10: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 11: North America Head and Neck Cancer Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 12: North America Head and Neck Cancer Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 13: North America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 14: North America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 15: North America Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 16: North America Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 17: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 18: Europe Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 19: Europe Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 20: Europe Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 21: Europe America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 22: Europe Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 23: Europe Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 24: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 25: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 26: Asia Pacific Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 27: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 28: Asia Pacific America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 29: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 30: Asia Pacific Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 31: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 32: Latin America Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 33: Latin America Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 34: Latin America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 35: Latin America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 36: Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 37: Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Middle East & Africa America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022-2031
  • Figure 39: Middle East & Africa America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 40: Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 41: Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 42: Global Head and Neck Cancer Market Share Analysis, by Company (2022)